Abstract
Similarly to a series of chronic diseases, essential arterial hypertension (HTN) may be manifested during childhood as a blood pressure (BP) reading which repeatedly rises above the 95th percentile of population-specific standards. Since BP tends to track along the same percentiles throughout life, children with higher BPs are more likely to become hypertensive adults. When healthy measures aimed at reducing BP (i.e. body weight reduction, aerobic physical exercise, low sodium intake) have failed, pharmacological treatment is usually required. This paper aims to undertake a review of antihypertensive pharmacological therapy in children, examining the drugs used in chronic treatment as well as those administered to treat hypertensive crisis (i.e. a BP major than 99th percentile of paediatric normograms). Moreover, several important differences registered in the therapeutic approach to paediatric HTN between US and European Guidelines will be underlined.
Keywords: Blood pressure, children, drugs, guideline, paediatric hypertension, therapy.
Current Medicinal Chemistry
Title:Antihypertensive Therapy in Children: Differences in Medical Approach Between the United States and Europe
Volume: 21 Issue: 27
Author(s): P.P. Bassareo, V. Bassareo, N. Iacovidou and G. Mercuro
Affiliation:
Keywords: Blood pressure, children, drugs, guideline, paediatric hypertension, therapy.
Abstract: Similarly to a series of chronic diseases, essential arterial hypertension (HTN) may be manifested during childhood as a blood pressure (BP) reading which repeatedly rises above the 95th percentile of population-specific standards. Since BP tends to track along the same percentiles throughout life, children with higher BPs are more likely to become hypertensive adults. When healthy measures aimed at reducing BP (i.e. body weight reduction, aerobic physical exercise, low sodium intake) have failed, pharmacological treatment is usually required. This paper aims to undertake a review of antihypertensive pharmacological therapy in children, examining the drugs used in chronic treatment as well as those administered to treat hypertensive crisis (i.e. a BP major than 99th percentile of paediatric normograms). Moreover, several important differences registered in the therapeutic approach to paediatric HTN between US and European Guidelines will be underlined.
Export Options
About this article
Cite this article as:
Bassareo P.P., Bassareo V., Iacovidou N. and Mercuro G., Antihypertensive Therapy in Children: Differences in Medical Approach Between the United States and Europe, Current Medicinal Chemistry 2014; 21 (27) . https://dx.doi.org/10.2174/0929867321666140304093848
DOI https://dx.doi.org/10.2174/0929867321666140304093848 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Effect of SEX/Gender on Cardiovascular Pharmacology
Current Pharmaceutical Design The Role of Inflammatory Biomarkers in the Detection and Therapy of Atherosclerotic Disease
Current Vascular Pharmacology Endothelial Progenitor Cells as a Therapeutic Approach for Intracerebral Hemorrhage
Current Pharmaceutical Design Fetal Programming of the Human Brain: Is there a Link with Insurgence of Neurodegenerative Disorders in Adulthood?
Current Medicinal Chemistry Physiological Mechanisms of Action of Incretin and Insulin in Regulating Skeletal Muscle Metabolism
Current Diabetes Reviews T9-T10 Osteomyelitis, Epidural Abscess and Cord Compression Secondary to <i>Mycobacterium abscessus</i>: A Case Report
Infectious Disorders - Drug Targets Auto-Antibodies As Possible Markers and Mediators of Ischemic, Dilated, and Rhythmic Cardiopathies
Current Drug Targets Association between HbA1C (Glycated Hemoglobin) and Clinical Outcomes in Patients with Subarachnoid Hemorrhage After Neuro-intervention
Current Neurovascular Research Dipeptidyl Peptidase-4 Inhibitor Induced Angioedema – An Overlooked Adverse Drug Reaction?
Current Diabetes Reviews The Heat Shock Connection of Metabolic Stress and Dietary Restriction
Current Pharmaceutical Biotechnology Brain Aging in African-Americans: The Atherosclerosis Risk in Communities (ARIC) Experience
Current Alzheimer Research Patent Selections
Recent Patents on Biomarkers The Significance of Endothelium-Derived Hyperpolarizing Factor in the Human Circulation
Current Vascular Pharmacology Chronic Kidney Disease and Cardiovascular Disease: A Focus on Primary Care
Cardiovascular & Hematological Disorders-Drug Targets Effects of Antiplatelet Medication on Arteriovenous Fistula Patency After Surgical Thrombectomy
Current Vascular Pharmacology Discovery of Novel Scaffolds for Rho Kinase 2 Inhibitor Through TRFRET- Based High Throughput Screening Assay
Combinatorial Chemistry & High Throughput Screening Heart Failure in North America
Current Cardiology Reviews Editorial (Thematic Issue: Induced Pluripotent Stem Cells (iPSCs) in the Gastroenterology and Hepatology: from Basic Research to Clinical Applications)
Current Stem Cell Research & Therapy Hyperhomocysteinemia and Endothelial Dysfunction
Current Hypertension Reviews Will it Ever Become Possible to Prevent Dopaminergic Neuronal Degeneration?
CNS & Neurological Disorders - Drug Targets